Quantum Motion Secures $160.0M

Scarlet Therapeutics Ltd

Scarlet Therapeutics is developing a unique platform that generates novel red blood cell-based therapeutics to potentially treat a wide range of diseases. Initially targeted at the rare metabolic diseases, hyperammonemia and hyperoxaluria, this approach could also be used more broadly to target other metabolic diseases, cancer and autoimmune diseases. These therapeutic red blood cells (tRBCs) are very similar to standard red blood cells, having many unique qualities compared to systemic administration of therapeutic protein, including pervasive reach throughout the body, a long life and the ability to carry the active proteins within the tRBC, thereby shielding them from the immune system. Born out of more than a decade of research at the University of Bristol and its learnings from the RESTORE clinical study, Scarlet also has an exclusive commercial licence for the widely used BEL-A cell line, which provides an alternative platform technology for production of red blood cells.

CodeWords

Turn words into AI agents and automations.

Myomaker Bio

Myomaker Bio is a contract research organisation (CRO) specialising in pre-clinical muscle biology. We partner with biotech and pharmaceutical companies to deliver tailored testing solutions that assess the impact of compounds on muscle function, enabling informed decision-making and accelerating development pipelines. Our expertise spans advanced human and animal muscle models, including 3D human skeletal muscle, iPSC-derived systems, neuromuscular junctions, and vascularised bioengineered models. We provide comprehensive assessment of muscle morphology and function across disease, exercise, injury, and rehabilitation contexts, delivering high-quality, actionable data.

OpenTrade

OpenTrade provides an institutional grade platform for yield products designed for fintechs and institutional investors across Web2 and Web3 ecosystems. Our offerings combines a technology platform with legal and operational frameworks and services that together support safe, compliant, and scalable yield products for the next generation of financial services & markets.

CellCentric

Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally. p300/CBP are twin (paralogue) acetyl transferases, and importantly, gene activating proteins that are known to play an important role in the progression of certain cancers. CellCentric’s pioneering drug is in Phase I/II clinical trials to evaluate its effectiveness to treat specific solid tumours, as well as haematological malignancies (blood cancers). These represent major clinical unmet needs, delivering a new therapy for people with cancer, who otherwise have few alternatives.